Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 4/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | SMO | Q99835 | 2/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1195174 | 0.80 | P2RX7 (0.59) | P2RX7MAPK14MAPK1MAPTSMO | |
| SCHEMBL1195290 | 0.79 | P2RX7 (0.60) | P2RX7MAPK14MAPK1MAPTSMO | |
| SCHEMBL1195233 | 0.77 | NR4A3 (0.49) | P2RX7MAPK14MAPK1MAPTSMO | |
| SCHEMBL1194321 | 0.77 | P2RX7 (0.61) | P2RX7MAPK14MAPTRAB9A | |
| SCHEMBL1195016 | 0.65 | MAPK1 (0.58) | P2RX7MAPK1MAPTSMORAB9A | |
| SCHEMBL25440035 | 0.65 | MAPT (0.62) | P2RX7MAPK1MAPT | |
| SCHEMBL5678545 | 0.65 | PTPN1 (0.46) | MAPTPTPN1RAB9ANR3C1 | |
| SCHEMBL13140239 | 0.64 | P2RX7 (0.53) | P2RX7MAPTSMORAB9A | |
| SCHEMBL1194641 | 0.64 | DRD2 (0.51) | MAPK1MAPTRAB9A | |
| SCHEMBL3495616 | 0.64 | ALDH1A1 (0.53) | MAPK1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155685-B1 | PYRAZOLE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LTD (GB) | 2011-03-16 | — | — | EP | disclosed |
| US-20110046137-A1 | Pyrazole Derivatives as P2X7 Modulators | GLAXO GROUP LIMITED | 2011-02-24 | — | — | US | disclosed |
| EP-2155685-A1 | PYRAZOLE DERIVATIVES AS P2X7 MODULATORS | Glaxo Group Limited (GB) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008138876-A1 | PYRAZOLE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046137-A1 | Pyrazole Derivatives as P2X7 Modulators | P2RX3, P2RX7, P2RX1 | P2RX7 2/4885MAPK14 472/4885MAPK1 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.